Short-winded.

In this retrospective study of >20K patients with non-small cell lung cancer, those getting nivolumab + an EGFR-targeted agent (together or in sequence) had 5x the odds of interstitial pneumonitis than those getting either agent alone. | Oshima, JAMA Oncol 2018